Lyra Therapeutics has treated the first subject in the Part one/non-randomised portion of the Phase II BEACON clinical trial of its investigational product candidate, LYR-220, in adults with post-surgical chronic rhinosinusitis (CRS).

Leveraging the XTreo platform of the company, LYR-220 is a bioresorbable polymeric matrix.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

LYR-220 is intended to offer up to six months of continuous local, intra-nasal, anti-inflammatory mometasone furoate drug therapy to the sinonasal passages of CRS patients who had a sinus surgery.

For CRS patients with enlarged nasal cavity as a result of sinus surgery but still need medication to control CRS symptoms, LYR-220 offers a non-invasive substitute to repeated sinus surgery.

The company anticipates topline data from Part one of the BEACON trial by the end of this year.

See Also:

The controlled, parallel-group trial will analyse the safety, tolerability, pharmacokinetics and efficacy comparing two designs of LYR-220 (7500µg MF) to control for 24 weeks in nearly 70 symptomatic adult CRS patients who had a bilateral sinus surgery.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

A non-randomised, open-label study, Part one of the trial will analyse the feasibility of placement enhancing the procedure while Part two will be a patient-blinded, 1:1:1 randomised assessment of two designs compared to sham control.

The company plans to conclude subject enrolment for the full BEACON trial by this year end.

Lyra Therapeutics president and CEO Maria Palasis said: “This represents a significant milestone for Lyra as we advance our second CRS product candidate into late-stage development, positioning us to potentially be the first to offer solutions for the full spectrum of CRS patients treated by ENT physicians.

“We look forward to advancing LYR-220 through the clinic and leveraging the path of LYR-210, our investigational therapy for CRS patients with surgically-naïve anatomy, currently in a pivotal Phase III trial (ENLIGHTEN I), for future regulatory filings.”